What are the side effects of Erdafitinib?

Erdafitinib is a kinase inhibitor used to treat susceptible FGFR3 or FGFR2 genetic alterations and those with to Adult patients with locally advanced or metastatic urothelial carcinoma (mUC) who have progressed during or after less than one prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Common side effects of Erdafitinib include increased phosphate (76%), stomatitis (56%), fatigue (54%), increased creatinine (5 2%), diarrhea (47%), increased alanine aminotransferase (41%), increased alkaline phosphatase (41%), methylaconeneum (41%), decreased sodium (40%), Decreased appetite(38%), Decreased albumin(37%), Disturbance to taste(37%), Decreased hemoglobin(35%), Dry skin(34%), Valley Elevated oxaline aminotransferase(30%), Decreased magnesium content(30%), Constipation(28%), Dry eye syndrome(28%), Palms-Abnormal red blood cell sensation in soles (26%), Hair loss(26%), Decreased phosphate(24%), Abdominal pain(23%), Increased calcium levels (22%), Nausea(21%), musculoskeletal pain(20%), thrombocytopenia(19%), leukopenia(17%), blurred vision(17%), paronychia(17%) , Urinary tract infection (17%), Increased potassium (16%), Weight loss (16%), Fever (14%), Vomiting (13%), Nail discoloration span>(11%), conjunctivitis(11%), oropharyngeal pain(11%), hematuria(11%), arthralgia(11%), decreased sodium content(16%), etc. The dosage of generic drugs is the same as that of the original drug, but the price is favorable. Each box of generic drugs is about 2more than a thousand. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0